Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comcast Corporation (CMCSA) vs Novavax Inc (NVAX) Price & Performance

Comcast CorporationTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Comcast Corporation vs Novavax Inc — how do they compare? Comcast Corporation trades at $23.28 (market cap $82.84B), while Novavax Inc trades at $8.44 (market cap $1.38B). The key difference: Comcast Corporation is far larger — about 60× Novavax Inc's market cap, and Comcast Corporation pays a 5.69% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

CMCSANVAX
Market Cap
$82.84B$1.38B
Sector
MediaHealth
52-Week High
$33.81$11.19
52-Week Low
$22.32$6.22
Enterprise Value
$167.98B$889.29M
Dividend Yield
5.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comcast Corporation

Comcast (CMCSA) trades at $23.97, up 1.7% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 16.16% net margin and attractive valuation metrics including P/E of 4.7 and P/B of 0.97. Recent quarterly earnings consistently beat expectations, while strategic moves include the NBCUniversal spin-off and Sky's acquisition of ITV's media unit for $2.14 billion.

The stock presents compelling value with significant upside to the $29.94 consensus target. However, investors face risks from Starlink competition and integration challenges from recent acquisitions. Wall Street maintains strong buy sentiment with 58% analyst support, but execution risks and sector disruption threats warrant careful monitoring.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

About Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.

Read more on CMCSA

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX